Bruker Reports Strong Q3, Considerable TOF/TOF Sales to Academic Institutions

Having spilled some of its goodies already in an October presentation at an investors’ meeting (see ProteoMonitor, 10-21-02), Bruker Daltonics formally reported last week that its revenues were up 22 percent for the third quarter. These revenues totaled $29.7 million, compared to $23.8 million in the third quarter of 2001. The company’s net income totaled $1.7 million, up from $925,000 in the previous year’s third quarter.